Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
Barbara Ann Karmanos Cancer Institute
Study ID
NCT00258232
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving celecoxib together with capecitabine and irinotecan may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving celecoxib together with capecitabine and irinotecan works in treating patients with recurrent or metastatic colorectal cancer.

Key Dates

Start date
Jan 31, 2002
Status verified
Apr 2013
Primary completion
Mar 31, 2007
Completion
Aug 31, 2007

Study Design

Primary purpose
TREATMENT

Primary Outcome Measure

Response rate by RECIST criteria at every other course

Locations (3)

FacilityCityStateZIPSite coordinators
University of Michigan Comprehensive Cancer CenterAnn ArborMichigan48109-0944-
Barbara Ann Karmanos Cancer InstituteDetroitMichigan48201-1379-
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State UniversityColumbusOhio43210-1240-

Find similar trials in Ann Arbor, MI

By condition
Colorectal cancer
By specialty
OncologyGI oncology
By research site
University of Michigan Comprehensive Cancer Center· Ann Arbor, MIBarbara Ann Karmanos Cancer Institute· Detroit, MIArthur G. James Cancer Hospital and Solove Research Institute at Ohio State University· Columbus, OH

Related Studies